Objective-Vascular calcification is associated with increased risk of myocardial infarction and stroke. The objective of this work was to examine the ability of 17β-estradiol (E2) to stimulate calcification of vascular smooth muscle cells (VSMC) in vivo, using aged apolipoprotein E-null mice with advanced atherosclerotic lesions, and subsequently to explore underlying mechanisms in vitro. Approach and Results-Silastic E2 capsules were implanted into male and female apolipoprotein E-null mice aged 34 weeks.
V ascular calcification is a common complication of atherosclerosis associated with increased risk of cardiovascular mortality. [1] [2] [3] [4] Considerable work has been undertaken over the past 2 decades aimed at elucidating the nature of mineralization processes in the vasculature. Although the processes are still incompletely understood, it is now well recognized that vascular calcification is an active, regulated process that shares mechanistic overlap with bone formation. 5, 6 In the vasculature, instead of osteoblasts driving calcification, vascular smooth muscle cells (VSMCs) undergoing differentiation to an osteogenic phenotype are thought to be a major calcifying type, [7] [8] [9] although not exclusively so. 10, 11 In response to hyperphosphatemia and the presence of other stimulants, VSMCs can enter an osteoblast-like differentiation program that may involve a program of VSMC dedifferentiation before osteogenic redifferentiation or a more direct form of transdifferentiation. [11] [12] [13] [14] VSMCs in culture and in calcifying atherosclerotic plaques can express bone-related proteins, such as bone sialoprotein (BSP), osteopontin (OPN), osteocalcin (OCN), collagen I and II, as well as osteoblastic differentiation factors, such as bone morphogenetic protein 2. 12, [15] [16] [17] The exact mechanisms driving differentiation are unknown, but may arise because of loss of mineralization inhibitors, such as matrix Gla protein (MGP) or OPN. [18] [19] [20] [21] It has been appreciated for some time that estrogens act on cells within bone to bring about mineralization and bone formation. Investigations have indicated that estrogen replacement attenuates bone loss 22 by stimulating osteoblasts 23 and inhibiting osteoclasts. 24 It has long been hypothesized that estrogens may have similar effects on the vasculature. In vitro, studies have shown that 17β-estradiol (E2) treatment can increase calcification in calcifying vascular cells, a subpopulation of bovine aortic medial cells. 25 However, other studies have demonstrated an inhibitory role for E2 in VSMC calcification in vitro. 26, 27 In the context of atherosclerosis, studies support a protective effect of E2 on plaque calcification in women, based on the cardiovascular protective effects of E2 that reduce total plaque burden, attributable to modulation of traditional risk factors, such as plasma high-density lipoprotein and low-density lipoprotein. 28, 29 In the clinic, studies show low serum E2 levels associate with increased coronary artery calcification (CAC), [30] [31] [32] whereas E2 replacement in younger menopausal women reduces CAC. 33, 34 These findings are supported by animal studies that show E2 protects against atherosclerotic plaque calcification when associated with beneficial effects on plaque progression. 27, 35 However, the mechanistic similarities to bone formation suggest that estradiol could promote vascular calcification in certain circumstances. This dilemma continues to raise the question of how estrogens impact on vascular calcification and plaque progression in the longer term, particularly in the aging vasculature, 36, 37 where established, more advanced lesions show a reduced antiatherosclerotic response to exogenous estrogen treatment in females. 37, 38 In men, administration of exogenous estrogens has long been associated with adverse cardiovascular outcomes. 39 In the current study, we use the apolipoprotein E-null mouse model of atherosclerosis and VSMC culture to provide a definitive account of the ability of E2 to promote differentiation of VSMCs to osteoblast-like calcifying cells and to promote subsequent vascular calcification and investigate a potential role for the classical estrogen receptors (ERs) in this process.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

E2 Site Specifically Enhances Plaque Calcification in the Absence of Concomitant Changes to Plaque Progression or Lipid Levels
After 8 weeks of E2 treatment, serum E2 levels in female mice were elevated 2-fold (P<0.05) compared with control animals, consistent with an increase in mean uterine weight (P<0.001). Female mice showed no significant alteration in serum concentrations of testosterone, total cholesterol, or high-density lipoprotein cholesterol (Table 1) . In male mice, serum E2 levels increased 2-fold (P<0.01), whereas testosterone levels decreased 2-fold (P<0.001). No significant change in total cholesterol or high-density lipoprotein cholesterol occurred in response to E2 treatment in male mice (Table 1) .
Histological analysis of the aortic sinus and innominate artery 8 weeks after subcutaneous insertion of E2 silastic implant showed that both control and treated mice had established, advanced lesions present at both vascular sites. Calcification was greater in the innominate lesions compared with aortic sinus lesions ( Figure 1A and 1B) . In female mice, E2 had no significant effect on plaque area ( Figure 1C and 1D) . However, plaque composition analysis showed that E2 treatment had no effect on calcified area in the innominate artery ( Figure 1E ), whereas E2 administration significantly increased calcified area in the aortic sinus (P<0.05; Figure 1F ). In male mice, E2 increased plaque area in the innominate artery but without concomitant changes in calcification at this site ( Figure 1C and 1E ). In contrast, E2 increased calcification in the aortic sinus (P<0.05) without augmenting plaque area ( Figure 1D and 1F). The ratio of calcified area to plaque area increased significantly in the aortic sinus in both male and female E2-treated mice ( Mean values ±SEM are presented and the level of significance for the differences between treatment groups and corresponding controls was determined using 1-way ANOVA. Female (control, n=14; E2, n=10); male (control, n=16; E2, n=15). E2 indicates β-estradiol; HDL, high-density lipoprotein; NS, not significant; and T, testosterone. numbers in sections taken from either the aortic sinus or the innominate artery, in both male and female mice (Figure 2A and 2D). In contrast, although ERβ-immunoreactive cell numbers remained unchanged in the innominate artery in response to E2, there was a 60% decrease in the proportion of ERβ-immunoreactive cells in the aortic sinus in female animals (P<0.05) and male animals (P<0.01; Figure 2B and 2D). E2 treatment had no effect on the proportion of AR-positive nuclei in either sex or at either site ( Figure 2C and 2D).
Laser capture microdissection followed by RNA extraction, reverse transcription and digital polymerase chain reaction of vascular SMCs in areas immediately adjacent to heavily calcified regions was performed on sections of the aortic sinus from female animals to confirm the immunohistochemistry results for ERα, ERβ, and AR, as well as osteoblast-like markers of the aortic sinus. Reverse transcription and digital polymerase chain reaction showed ERα mRNA levels were unchanged, whereas ERβ mRNA levels decreased with E2 treatment (P<0.001; Figure 3A ). In contrast to the immunostaining results, E2 significantly decreased AR mRNA levels (P<0.001; Figure 3A ). Quantitative analysis of MGP, BSP, and collagen II by digital polymerase chain reaction revealed that treatment with E2 reduced expression of the mineralization inhibitor, MGP (P<0.01), but elevated expression of the osteogenic markers, BSP, and collagen II (P<0.001; Figure 3B ).
Mineralization of Cultured Bovine Coronary Artery Smooth Muscle Cell Is Stimulated by E2 and ER Antagonists
Mineralization of vascular SMC was assessed in vitro by treating bovine coronary artery smooth muscle cells grown in calcifying medium with E2 in the presence or absence of ER antagonists and examining cellular calcium levels. After 7 days, E2 treatment significantly elevated calcium levels (P<0.001; Figure 4A ). This effect occurred in association with downregulation of ERβ (P<0.001) but not ERα mRNA levels, as measured by digital polymerase chain reaction ( Figure 4B ). In addition, E2 treatment downregulated AR mRNA levels (P<0.001).
Cotreatment of cells with E2 and either the ERα antagonist, MPP (1,3- 
, did not attenuate E2-stimulated calcification, but further increased calcification levels over and above that of E2 alone (MPP: P<0.05; PHTPP: P<0.001; Figure 4A ). Similarly, cotreatment with the dual ERα/β antagonist, ICI 182,780, had an additive effect on calcium deposition (P<0.001; Figure 4A ), suggesting suppression of classical ER expression or activity stimulates VSMC mineralization. Western analysis confirmed downregulation of ERβ in response to E2 at the protein level, which was augmented by cotreatment with the dual ER antagonist, ICI 182,780 ( Figure 4C ). Cotreatment of cells with E2 and AR antagonist, hydroxyflutamide, had no effect on E2-stimulated calcification ( Figure 4A ).
E2 and ER Antagonists Stimulate Differentiation of Bovine Coronary Artery Smooth Muscle Cells to an Osteogenic Phenotype
Digital polymerase chain reaction was used to monitor expression of osteoblast cell markers in response to E2 and the ER antagonists. After 3 days, the expression of 2 recognized inhibitors of calcification, MGP and OPN, was suppressed significantly in E2-treated cells (P<0.001; Figure 5A and 5B). Cotreatment with either of the 3 antagonists further suppressed MGP and OPN expression (P<0.001). E2 treatment significantly elevated expression of the osteoblast markers, OCN ( Figure 5C ), BSP ( Figure 5D ), collagen I ( Figure 5E ), and collagen II ( Figure 5F ). Cotreatment with the ER antagonists further increased expression of these markers with the dual ERα/ERβ antagonist consistently having a greater effect than the ER-specific antagonists alone (P<0.001; Figure 5C through 5F). The degree of MGP and OPN suppression and elevation of OCN, BSP, and collagen I and II levels was commensurate with the increment in calcification induced by these antagonists.
Osteogenic Differentiation and Mineralization of VSMCs Is Stimulated by ER Silencing
To confirm a role for ER downregulation in osteogenic differentiation and mineralization of VSMC, ERα and ERβ were silenced with siRNA targeting each receptor. Silencing achieved up to 70% mRNA knockdown ( Figure 6A ). Consistent with the promineralizing effects of the ER-specific antagonists, silencing of both ERα and ERβ significantly increased mineralization (P<0.001; Figure 6B ). In addition, silencing decreased MGP and OPN mRNA levels ( Figure 6C and 6D) and increased levels of OCN, BSP, collagen I, and collagen II (Figure 6E through 6H) .
Discussion
This study reports for the first time that exogenous E2 can promote calcification of advanced atherosclerotic lesions in aged male and female apolipoprotein E-deficient mice. The effect of E2 on calcification was dissociated from any concomitant increase in plaque size or change in lipid levels. Further exploration of mechanism showed that decreased classical ERβ was associated with in vitro and in vivo calcification and that antagonism or silencing of either ERα or ERβ promotes differentiation of VSMC to osteoblast-like calcifying cells in vitro. Together, this provides the first evidence that E2 can augment and direct independent calcification in advanced atherosclerotic plaques. Our findings are entirely consistent with the long-standing hypothesis that estrogens may influence vascular calcification 24 based on their ability to modulate osteoblast activity in bone 23, 40 together with the localization of osteoblast-like cells in calcified plaques. 15, 41 Molecular analysis showed that E2 treatment decreased ERβ levels in intimal cells in the aortic sinus in association with an effect on calcification. This effect was observed in both male and female animals. E2 suppression of ERβ was similarly replicated in VSMC in vitro, consistent with previous studies showing E2 can negatively autoregulate ERα and ERβ expression in various vascular cell types. 42, 43 Our finding is similar to that seen in preosteoblastic mesenchymal stem cells, where E2 stimulation of osteoblastic markers was associated with decreased ERβ. 43 Together, these results suggest an association between suppression of ERβ and a pro-osteogenic phenotype. A causal role in this association is supported by our in vitro finding that the ERβ antagonist, PHTPP, could increase VSMC calcification. The fact that the ERα antagonist and dual ERα/ERβ antagonist could also increase calcification and induce a mineralizing cell phenotype suggests both classical ERs are needed to sustain E2 protective effects. Given ER antagonists can act as ER agonists in some contexts depending on coregulator expression, 44 we could not preclude ER activation in these experiments. However, RNA silencing of ERα and ERβ in bovine coronary artery smooth muscle cells confirmed that receptor loss could directly augment osteogenic differentiation and mineralization of VSMCs. Inclusion of ERα as an agonist in this process gives some clarity to our earlier animal study, where testosterone-stimulated increases in plaque calcification were associated with decreased expression of ERα, not ERβ, in intimal cells. 41 Together, our results show that loss or antagonism at either or both ERs can promote VSMC differentiation and calcification in a conducive environment. The postreceptor mechanism whereby loss of ER-mediated activity promotes mineralization remains to be elucidated but may relate to the ability of ERs to transrepress other nuclear receptors. 45 There is a complex, often reciprocal, relationship between the AR and the ERs; however, findings of our previous study 41 and that of Zhu et al 46 clearly show a stimulatory role for the AR in VSMC mineralization in response to androgens. We tested whether AR downregulation plays any role in E2-stimulated mineralization in vitro and showed that an E2-AR mechanism is unlikely as blocking AR with hydroxyflutamide had no effect on E2-induced calcification of cultured VSMC. However, we cannot at this stage rule out that AR may mediate an E2 effect in vivo, even though AR levels are unchanged by E2 treatment in this context.
Our data conclusively show that suppression of classical ER activity induces VSMC differentiation to a mineralizing phenotype. The mechanism linking loss of ER activity to mineralization remains unclear. One hypothesis may be that ER loss in the presence of excess E2 may result in the increase of E2 and coactivator pool that can promote activation of other transcription factors or E2-binding proteins that direct promineralizing gene expression, as depicted in our hypothetical model (Figure 7) . Potential candidates may be the E2-binding G-protein receptor 30 that directs nongenomic effects of E2 from the plasma membrane. AR may be an agonist, given recent studies demonstrating a role for the AR in VSMC mineralization 41, 46 and previous evidence that E2 can act as an AR ligand. 47 However, this is unlikely as our in vitro results with an AR antagonist suggest that AR is not involved in E2 augmentation of calcification. Alternatively, the increased coactivator pool could potentially involve the estrogen-related receptor Figure 4 . Mineralization of bovine coronary artery smooth muscle cells (BCASMC) in response to β-estradiol (E2) and estrogen receptor (ER)-specific antagonists. A, Calcium deposition was measured as mean±SEM in BCASMC stimulated with β-glycerophosphate and exposed to E2 treatment with or without estrogen receptor alpha (ERα) antagonist (MPP), estrogen receptor beta (ERβ) antagonist (PHTPP), dual ERα/β antagonist (ICI 182,780), or hydroxyflutamide (HF) for 14 days (n=8). Calcium levels were determined and normalized to vehicle control (VC; 100%) for each experiment. B, ER and androgen receptor (AR) mRNA levels were measured as mean±SEM by digital polymerase chain reaction after total RNA was isolated from BCASMC (n=8). Statistical significance was determined using 1-way ANOVA with the Tukey post hoc test (*P<0.05, ***P<0.001). C, Representative Western blot of ERα and ERβ protein expression in response to E2 in the presence or absence of the dual ER antagonist, ICI 182,780 (n=2).
family of transcription factors (ERRα/-β/-γ). These orphan receptors do not bind E2 but share an overlapping, yet unique, set of cofactors and promoter binding sites with the ERs and also cross-talk in a divergent manner with other transcription factors like activating protein 1 through cell-specific cofactor interaction. 48, 49 The estrogen receptor-related receptors have a demonstrated role in promoting VSMC mineralization and bone formation and hence may be prime candidates for further investigation of these pathways with specific antagonist or silencing studies. 50, 51 Interestingly, we found that E2 had site-specific effects on both calcification and ERβ expression. E2 increased plaque calcification and decreased ERβ expression in the aortic sinus but not the innominate artery, in both male and female animals. This is consistent with our earlier study where sitespecific effects of testosterone and dihydrotestosterone on calcification and sex hormone receptor expression were observed in this model in both sexes. 41 The reason for the site dependency is unknown but may relate to differential mechanical shear effects in different vascular beds. Variable responses of vascular bed to endogenous or exogenous sex hormones have been noted. CAC and abdominal aortic calcification share similar risk factors; however, male sex is only associated with CAC, whereas abdominal aortic calcification has a stronger association with age [52] [53] [54] but in some studies has been shown to have higher prevalence in women. 55 Although reports on the Figure 5 . Effects of β-estradiol (E2) and estrogen receptor antagonists on calcification marker expression in cultured bovine coronary artery smooth muscle cells (BCASMC). mRNA levels of matrix Gla protein (MGP; A), osteopontin (OPN; B), osteocalcin (OCN; C), bone sialoprotein (BSP; D), collagen I (E), and collagen II (F) were measured as mean±SEM by digital polymerase chain reaction after total RNA was isolated from BCASMC stimulated with β-glycerophosphate and exposed to E2 treatment with or without estrogen receptor alpha (ERα) antagonist (MPP), estrogen receptor beta (ERβ) antagonist (PHTPP), or dual ERα/ERβ antagonist (ICI 182,780) for 14 days (n=8). Statistical significance was determined using 1-way ANOVA with the Tukey post hoc test (***P<0.001).
effects of hormone replacement therapy (HRT) on extracoronary sites such as the abdominal aorta are limited, one early observational study showed that HRT use was associated with reduced CAC but not abdominal aortic calcification. 52 In the latter study, it was postulated that differences in lesion stage at each site may have influenced the dichotomy. 56 In our animals, atherosclerotic lesions in the innominate artery grew in size between 34 and 42 weeks in the absence of any hormone treatment, whereas no plaque progression was observed in the aortic sinus over this period (data not shown). Advanced, static lesions may respond differently to advanced but actively growing lesions. Alternatively, the outcome may depend on the degree of plaque calcification before E2 administration, as we observed that plaque calcification was considerably higher in the innominate lesions relative to those in the aortic sinus. Others have suggested that the diverse embryonic origins of SMC in different vascular beds may account for the site-specific localization of vascular disease, 57 which may be relevant to the findings of this study. There is growing evidence that calcifying medial cells derive from various sources, such as adventitial mesenchymal stem-cell-like cells, myofibroblasts, or subintimal pericytes; proportions of these osteoprogenitors may differ between vascular beds and may also contribute to site-specificity. 17, [58] [59] [60] Further studies are required to examine these hypotheses or whether other genetic or environmental factors may influence local plaque mineralization. 52 Our findings in female apolipoprotein E-deficient mice, that E2 does not cause regression of lesions once established and no longer growing, is in keeping with past clinical HRT trials, which suggest that short-term HRT may not consistently prevent progression or destabilization of established atherosclerotic lesions in the coronary arteries of postmenopausal women. 61, 62 The timing hypothesis, that is, that hormone therapy initiated well after onset of menopause reduces the beneficial influence of estrogens on cardiovascular outcomes, originated from the discordance of these trials with outcomes of earlier observational studies that showed E2 benefit. 63 More recently, the ELITE trial (Early vs Late Intervention Trial With Estradiol) was designed to address this hypothesis and stratified effects of HRT based on years since menopause when HRT was commenced and examined carotid intimamedial thickness and CAC. 37 The trial showed that women Figure 6 . Effects of estrogen receptor (ER) silencing on β-estradiol (E2)-stimulated mineralization and calcification marker expression in cultured human coronary artery smooth muscle cell (HCASMC). A, Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) mRNA levels were measured by digital polymerase chain reaction (PCR) after RNA silencing. B, Calcium deposition was measured as mean±SEM in HCASMC stimulated with β-glycerophosphate and E2 for 14 days (n=5) after RNA silencing of ERα or ERβ. Calcium levels were determined and normalized to vehicle control (100%) for each experiment. mRNA levels of matrix Gla protein (MGP; C), osteopontin (OPN; D), osteocalcin (OCN; E), bone sialoprotein (BSP; F), collagen I (G), and collagen II (H) were measured as mean±SEM by digital PCR after total RNA was isolated from HCASMC (n=5) treated with β-glycerophosphate, E2 with or without RNAi. Statistical significance was determined using 1-way ANOVA with the Dunnett post hoc test (***P<0.001). siCTL indicates nontargeting siRNA control.
commencing HRT <10 years postmenopause had no benefit with respect to carotid intima-medial thickness in contrast to those commencing HRT <6 years postmenopause. Yet, there was no benefit of HRT on CAC in either cohort. These results are consistent with the timing hypothesis but also show sitespecific effects of E2 treatment. Taken together, these data are a reminder that our understanding of estrogen responsiveness in the vasculature of older women with more advanced disease remains limiting. In men, this study adds to the body of evidence, suggesting that exogenous E2 treatment in men is not beneficial to the cardiovascular system, 39 and now extends the potential adverse effects to calcification of the vasculature.
In this study, we investigated a long-held hypothesis that E2 can influence vascular calcification. 25 The findings are in contrast to many estrogen replacement studies (particularly in younger women) that show benefit, in line with the cardioprotective effects of E2 on traditional risk factors, such as serum cholesterol levels. The relationship in younger postmenopausal women is now well established; however, the paucity of studies in older postmenopausal women limits our understanding of E2 effects in this context, although studies are now addressing this issue. 36, 37 Replicating the postmenopausal state in animal models is challenging, and E2 replacement after ovariectomy elicits dramatic effects on plaque progression and lipid profiles 27 ; thus, such studies tend to replicate findings in studies of younger postmenopausal women. The use of gonadally intact animals, by us and others, 38 avoids the need to interpret the E2 effect on total plaque area caused by altered plasma cholesterol levels; however, the limitation associated with use of intact animals is the pharmacological levels of E2 achieved in the blood. Any physiological relevance of these findings to estrogen replacement studies in older women remains to be established; however, here we have given proofof-principle that in the absence of confounding factors, exogenous E2 administration can modulate vascular calcification in vivo, as long hypothesized. Furthermore, we have shown that this occurs through modulation of VSMC and osteogenic gene expression and have now clearly demonstrated a role for the classical ERs in modulating this osteogenic differentiation. A role for downregulation or antagonism of the ERs in promoting this change suggests that molecules other than estrogens that can affect ER, such as estrogen blockers/ antagonists, selective ER modulators, xenoestrogens, or even testosterone, 41 may potentially have promineralizing effects in the vasculature, which may be particularly important in they lack the cardioprotective effects of estrogens normally found in women.
In summary, we found that exogenous E2 treatment of aged male and female mice increased calcification of advanced atherosclerotic lesions, independent of plaque growth and lipid levels. We demonstrated a direct effect of E2 on calcifying pathways in vascular cells through promoting calcification by VSMC differentiation to osteoblast-like calcifying cells in vitro and in vivo. Furthermore, we have now identified a role for both classical ERs in driving this process. How the loss of ER activity stimulates a pro-osteogenic phenotype requires further study. The observation of site-specific E2 effects on ER expression and calcification in this study continue to highlight our limited understanding of the effects of estrogens and their receptors in the aging vasculature of both men and women.
